Hudson Bay Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Hudson Bay Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-203,291	Closed	-$6.81M	–	1664
2026 Q1	$6.81M	Buy	203,291 +202,952	+59,868%	+$7.96M	0.02%	405
2025 Q4	$15.7K	Sell	339 -22,023	-98%	-$1.21M	﹤0.01%	1142
2025 Q3	$1.51M	Sell	22,362 -44,990	-67%	-$3.34M	0.01%	793
2025 Q2	$5.64M	Buy	+67,352	New	+$5.04M	0.02%	514
2024 Q4	–	Sell	-17,220	Closed	-$869K	–	1095
2024 Q3	$869K	Sell	17,220 -12,780	-43%	-$612K	﹤0.01%	690
2024 Q2	$1.22M	Buy	+30,000	New	+$1.27M	0.01%	587
2015 Q1	–	Sell	-1,600	Closed	-$174K	–	199
2014 Q4	$174K	Buy	+1,600	New	+$330K	﹤0.01%	170

Hudson Bay Capital Management's SLNO Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 203,291 shares — an estimated $6.81M sold.

Hudson Bay Capital Management first reported a position in SLNO in Q4 2014 and held it in 7 quarters. The position peaked at $6.81M in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Hudson Bay Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Hudson Bay Capital Management sold 203,291 Soleno Therapeutics shares in Q2 2026, an estimated $6.81M.
Hudson Bay Capital Management first reported a position in Soleno Therapeutics in Q4 2014 and held it in 7 quarters.
Hudson Bay Capital Management's Soleno Therapeutics position peaked at $6.81M in Q1 2026.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.